Casticin from Sanse Powder release medium tested in rat knee osteoarthritis
In an abstract, casticin from the in vitro release medium of Sanse Powder reduced synovial fibroblast senescence and inflammation in a rat knee osteoarthritis model, linked to inhibition of FAK/PI3K/AKT phosphorylation. [1]
Automatic summary · not editorially reviewed
The key findings
The in vitro release medium of Sanse Powder was tested in a rat knee osteoarthritis model, and casticin, monocerin and chlorogenic acid were identified as major components. [1]
Casticin improved synovial pathology, reduced pro-inflammatory cytokines and chemokines, and decreased synovial fibroblast senescence in the reported experiments. [1]
The abstract attributes the effects to inhibition of FAK/PI3K/AKT phosphorylation, based on cell and rat experiments. [1]
The source at a glance
- Study type / format
- Preclinical laboratory study (abstract)
- Population / context
- Rats in a knee osteoarthritis model and cells in laboratory experiments; Sanse Powder release medium and its component casticin.
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Sanse Powder release medium and rat knee osteoarthritis
Sanse Powder (SSP) is described as clinically effective in knee osteoarthritis (KOA), but its active components and mechanisms were unclear. The researchers collected the in vitro release medium of SSP (SSP-IVRM) using an in vitro release test and evaluated its effects in a KOA rat model. Ultra-high-performance liquid chromatography-tandem mass spectrometry identified casticin (CAS), monocerin and chlorogenic acid as major components. Network pharmacology and molecular docking linked these compounds to PI3K signalling and cellular senescence.
Supporting source [1]
Casticin effects on synovial pathology and senescence markers
According to the abstract, casticin significantly improved synovial pathology, reduced pro-inflammatory cytokines and chemokines, modulated fibrosis- and senescence-related genes and proteins, and decreased synovial fibroblast senescence. Transcriptomic analysis further implicated cell adhesion and the PI3K-AKT pathway. Additional experiments indicated that casticin alleviates KOA-related inflammation and cellular senescence by inhibiting FAK/PI3K/AKT phosphorylation. These are experimental findings in rats and cells, not evidence of benefit for human lifespan or disease outcomes.
Supporting source [1]
Abstract-only scope of the casticin osteoarthritis study
This explainer is based only on the abstract; the full text was not reviewed. The abstract does not report sample sizes, follow-up duration, comparator details or effect sizes, so the strength and reproducibility of the findings cannot be judged here. The proposed mechanism involves signalling-pathway inhibition in cells and rats; it does not establish that casticin or Sanse Powder prevents or treats osteoarthritis in people, and no dosing or clinical recommendation follows from it.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Sample sizes, follow-up, comparator details and effect sizes are not reported in the abstract. Findings are from cells and rats and do not establish human clinical benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Liu J, Wu P, Jiang R, Jie L, Shi L, Fu H, Wei Y, Liu D, Wang P, Yin S, Mao J. · europepmc.org · October 1, 2026